Alnylam Pharmaceuticals vs Guardant Health

Alnylam Pharmaceuticals (ALNY), health care, and Guardant Health (GH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Alnylam Pharmaceuticals is worth $21B on the stock market and Guardant Health $19.4B: Alnylam Pharmaceuticals is valued at 8% more. Alnylam Pharmaceuticals's operating margin in its latest fiscal year was 13.5% and Guardant Health's -44.5%. Over the past year Alnylam Pharmaceuticals's share price has moved -65.4% and Guardant Health's +50.7%.

Key facts

Alnylam Pharmaceuticals market value
$21B
Guardant Health market value
$19.4B
Alnylam Pharmaceuticals P/E
7.9
Alnylam Pharmaceuticals revenue
$3.7BFY to 2025-12-31
Guardant Health revenue
$982MFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Alnylam Pharmaceuticals vs Guardant Health: every measure side by side
Measure Alnylam Pharmaceuticals Guardant Health
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$21Bhigher$19.4Blower
Revenue$3.7Bhigher$982Mlower
Earnings$313.7Mhigher-$416.3Mlower
Employees2,500higher2,490lower
Total assets$5Bhigher$2Blower
Valuation
P/E7.9—
P/S5.6lower19.7higher
P/B5.8—
Dividend yield0.00%0.00%
Profitability
Operating margin13.5%higher-44.5%lower
Balance sheet
Net assets$789.2Mhigher-$99.3Mlower
Total liabilities$4.2Bhigher$2.1Blower
Total debt—$1.5B
Cash on hand$1.7Bhigher$378.2Mlower
Price change
Today-2.02%lower-0.52%higher
1 year-65.4%lower+50.7%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Alnylam Pharmaceuticals / Guardant Health). Who owns ALNY · Who owns GH

Further comparisons

Learn

Questions and answers

Which is bigger, Alnylam Pharmaceuticals or Guardant Health?

By market value, Alnylam Pharmaceuticals is the larger: $21B against $19.4B for Guardant Health. By revenue in its latest fiscal year, Alnylam Pharmaceuticals is the larger: $3.7B against $982M for Guardant Health.

Which has the higher operating margin?

Alnylam Pharmaceuticals: 13.5%, against -44.5% for Guardant Health. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Alnylam Pharmaceuticals and Guardant Health?

In their latest 13F filings, Baillie Gifford team holds both.

Cite this page

Funkfolio, “Alnylam Pharmaceuticals vs Guardant Health”, data as of 18 November 2026. https://funkfolio.com/compare/alny-vs-gh

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.